Cardinal Health Inc. closed 5.54% short of its 52-week high of $139.50, which the company achieved on April 3rd.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Cardinal Health (CAH – Research Report). The ...

BofA raised the firm’s price target on Cardinal Health (CAH) to $155 from $150 and keeps a Buy rating on the shares. The recent introduction of ...

BofA raised the firm’s price target on McKesson (MCK) to $755 from $665 and keeps a Buy rating on the shares. The recent introduction of ...

BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent ...

Cardinal Health (CAH) closed the latest trading day at $128.88, indicating a -1.2% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 3.46%.

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

The stock's rise snapped a four-day losing streak.

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging ...

Following recent U.S. Food and Drug Administration (FDA) approval 2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability across a wide ...

Opioid settlements with companies like Purdue Pharma, Walmart, and Johnson & Johnson have led to headline-grabbing ...